[Inhibition effects of tumor infiltrating lymphocytes from oral cancer on nude mice transplanted tumor established with human tongue carcinoma cell lines].
OBJECTIVE
To observe the in vivo inhibition effects on nude mice transplanted tumor with tumor infiltrating lymphocytes (TILs) isolated from primary mass of oral cancer.


METHODS
Established the transplanted tumor model of human tongue cancer at the back of BALB/C nude mice with subcutaneous injection of squamous cell carcinoma lines Tca 8113. TILs isolated from patients with Oral cancer, combining with low dose of cyclophosphamide (Cy: 50 mg/kg), were locally injected into the peripheral site of tumor. The inhibition rate (IR) was calculated by the volume of tumor mass from the 1st to the 8th week, and the weights at the 8th week after tumor dissection.


RESULTS
1. Group TIL + rIL-2 and group TIL + rIL-2 + Cy both exerted a strong inhibition effect on the transplanted tumor within three weeks. The Inhibition rate (IR) were 86.1% +/- 0.4% and 97.7% +/- 0.6% respectively at the 3rd week, while 32.1% +/- 0.3% and 80.6% +/- 0.3% at the 8th week. 2. TIL + rIL-2 + Cy expressed a stronger effect and a longer inhibition time. The IR of TIL + rIL-2 and TIL + rIL-2 + Cy were 20.0% +/- 1.4% and 75.5% +/- 2.5% respeetively at the 8th week (P < 0.01).


CONCLUSIONS
This study demonstrated that TILs from patients with oral carcer possess strong in vivo inhibition on nude mice transplanted tumor, and low dose of cyclophasophamide can enhance the inhibition effect and prolong the inhibition time.
Liao
G
G
School of Stomatology, Sun Yat-Sen University of Medical Sciences, Guangzhou 510060.
Mao
Z
Z
Xu
P
P
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009062:Mouth Neoplasms / Q000276:immunology*; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D014062:Tongue Neoplasms / Q000517:prevention & control*; D014407:Tumor Cells, Cultured
D007376:Interleukin-2; D011994:Recombinant Proteins; D003520:Cyclophosphamide